➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Baxter
Merck
Express Scripts
Dow

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 8,927,530

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,927,530
Title:Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
Abstract: The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, useful in the treatment of tumors. ##STR00001##
Inventor(s): Valsasina; Barbara (Milan, IT), Beria; Italo (Nerviano, IT), Ciavolella; Antonella (Bizzarone, IT), Ballinari; Dario (San Donato Milanese, IT), Pesenti; Enrico (Parabiago, IT), Croci; Valter Domenico (Nerviano, IT), Moll; Juergen (Appiano Gentile, IT)
Assignee: Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT)
Application Number:13/321,024
Patent Claims:see list of patent claims

Details for Patent 8,927,530

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT) 2029-05-26 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT) 2029-05-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT) 2029-05-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT) 2029-05-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Express Scripts
Harvard Business School
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.